NCT06263673CompletedPhase 4
Anti-Diabetic Medications to Fight PD and LBD
Anti-Diabetic Medications to Fight Parkinson's Disease and Lewy Body Dementia
Source: ClinicalTrials.gov · Last updated 28 Jan 2026
Brief summary (registry, in English)
The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 9 Feb 2024
- Start date
- 7 May 2024
- Primary completion date
- 8 Jan 2025
- Lead sponsor
- Mayo Clinic
- Diseases
- Lewy body dementia, Parkinson disease
- NCT number
- NCT06263673
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 18
- From 7 May 2024 to the primary completion date, 8 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of high dose steroids.
- Current systemic chemotherapy.
Other illness
- Use of insulin or other anti-diabetes medications other than metformin.
- Bleeding disorder, use of anticoagulants, thrombocytopenia, or severe anemia.
- Recent (within 30 days) or recurrent (defined as more than one in the past 12 months) urinary tract infection or yeast infection.
Lab values
- Contraindication to taking a DPP4 inhibitor or SGLT2 inhibitor including: allergy, history of angioedema, pancreatitis, active gallbladder disease, renal impairment with EGFR \< 45).
Other
- Pregnancy or breastfeeding.
- Other contraindication that would make study participation unsafe or make study related data unable to be interpreted.
Who the study is looking for
- Parkinson's disease or Lewy Body Dementia (diagnosis confirmed by neurologist at Mayo Clinic) with stable neurological treatment in the past approximately three months.
- Glucose intolerance or mild diabetes: The American Diabetes Association criteria for pre-diabetes/ glucose intolerance includes fasting glucose 100-125, random glucose 140-199, or hemoglobin A1C 5.7-6.4% and diabetes is \> 125 mg/dL, \> 200 mg/dL, and 6.5% or greater, respectively (40). It has been previously reported that 50-80% of individuals with Parkinson's disease have abnormal glucose tolerance (17), so this should not limit recruitment.
Age in the registry: 45 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic Florida Coordinator of this site? Confirm its status | Jacksonville | United States | Unknown status |
Related publications
- Anti-diabetic medications to fight Parkinson's disease and dementia with Lewy bodies: a pilot study.Front Neurol · 2026 · PMID 42318251
This page is information, not medical advice. Discuss any trial with your doctor.